In silico models applied in medical physics are valuable tools to assist in treatment optimization and personalization, which represent the ultimate goal of today's radiotherapy. Next to several biological and biophysical factors that influence tumour response to ionizing radiation, hypoxia and cancer stem cells are critical parameters that dictate the final outcome. The current work presents the results of an in silico model of tumour growth and response to radiation developed using Monte Carlo techniques. We are presenting the impact of partial oxygen tension and repopulation via cancer stem cells on tumour control after photon irradiation, highlighting some of the gaps that clinical research needs to fill for better customized treatment.
INTRODUCTION
In silico models in cancer treatment are simplified tools to reproduce the biological world. While models do not reflect all the fine details of the real systems, simulation via computer modelling has several advantages: kinetic parameters can be easily changed and results rapidly obtained, various mechanisms can be studied in isolation determining their impact on specific processes, extreme values for different parameters may be considered and limiting factors determined for biologically valid results. The aim of this work is to present some of the results obtained using an in silico model of tumour growth and behaviour during radiotherapy.
Tumours of different origins follow different growth kinetics and dynamics, therefore accurate modelling requires specific and well-determined parameters that characterize each particular group of tumours. In this work, the growth and behaviour of head and neck cancers is simulated, as well as their response to ionizing radiation.
Treatment of head and neck cancers is still a challenge, due to their resistance that is mainly dictated by cellular repopulation during radiotherapy and high levels of hypoxia. Hypoxia is a challenging factor in low LET (linear energy transfer) radiotherapy [1] , which includes the most commonly used photon and electron beams produced by the clinical linear accelerators.
There are two types of radiobiological hypoxia: acute (or perfusion-limited) and chronic (or diffusion-limited) (see Fig. 1a and 1b) . The latter one generally occurs in the core of large tumours, due to the distance from the neighbouring blood vessels which does not allow diffusion of blood and nutrients to the respective cells. This type of hypoxia is managed through fractionated radiotherapy, which allows for tumour reoxygenation in between dose fractions as the tumour shrinks. However, the other form of hypoxia which is limited by blood perfusion, occurs due to tumour angiogenesis, the process of new blood vessel formation which is necessary for the tumour to develop into a malignant entity. Due to the abnormal geometry and functionality of these tumour-triggered blood vessels, there are often leakages and obstruction that would interfere with blood flow in certain regions of the tumour. This temporal lack of oxygenation caused by the limitation of blood perfusion can cause patches of hypoxic areas throughout the tumour, in a highly fluctuating pattern both temporally and spatially. This type of hypoxia is the more clinically challenging and the one that has been implemented in the current Monte Carlo model through its stochastic nature. Another critical parameter for tumour growth and development is the fraction of cancer stem cells (CSC) [2] . CSCs are cells that can self-renew themselves (i.e. recreate through division) and have the ability for indefinite proliferation [3] , features that are responsible for tumour progression, repopulation and also treatment failure. Usually, CSCs divide asymmetrically, meaning that the result of cell division is a CSC (through self-renewal) and another cell type (for example a differentiated cell). However, CSCs can also divide symmetrically, situation when the two cells created are both cancer stem cells (see Fig. 2 ). This scenario is common during treatment, as a response to cell loss, and leads to a more rapid growth and tumour repopulation. 
METHODS

Monte Carlo technique-based tumour development
This work is based on an in-house developed computer program that employs a Monte Carlo decision-making method. The code has several modules written in C++ language which are used to create a virtual tumour and then to simulate various radiotherapy schedules. A Monte Carlo technique has been used to achieve the same probabilistic nature observed in clinical settings. Given that there is no analytical method that fully describes the development of a carcinoma and its response to various therapies, we considered that the Monte Carlo technique using statistically obtained parameters is a closer representation of the truth occurring in biological systems.
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The growth of the virtual head and neck tumour starts from a single CSC, which, in the division phase of the cell cycle (mitosis) recreates itself and also gives birth to a daughter cell. The probability for the daughter cell to be also a CSC is 1.9% (see Table 1 ), value that has been established through multiple iterations in order to achieve a tumour growth with biologically realistic parameters [4] . The tumour growth process follows a Monte Carlo approach that takes stochastic decisions based on input parameter values obtained from the literature (Table 1 ) [5] . The tumour growth module generates a probabilistic value for the type of new cell to be created. Beside CSCs, the virtual tumour is made of differentiated cells (D) that are non-stem cancer cells with a limited proliferative ability and quiescent cells (Q) which are cells that reside in the outer phase of the cell cycle and can be triggered into the cycle by various stimuli, including cell loss due to radiotherapy. Being a rapidly proliferating tumour, the average length of the cell cycle for a head and neck cancer cell is 33h, ranging between 20-60h [6] . To be in agreement with the literature data, the cell cycle time of each cell is generated through an asymmetrical Gaussian distribution, that is truncated at one standard deviation towards lower values and two standard deviations towards higher values .
Each cell of the tumour is followed individually, knowing its type, length of its cell cycle, position in the cycle, the number of generation, its hypoxic / oxic status. A set of statistical results are generated every 24 hours based on the current state of the model. This data is stored in a result file for later analysis. All random generators used by the model employ the Mersenne Twister algorithm in its 32 bit implementation, in order to generate good quality random numbers at sensible speed. 
Implementation of tumour hypoxia and the impact on response to radiotherapy
As shown in Table 1 , a range of hypoxia values quantified by the partial oxygen tension has been considered in the simulation, from severely hypoxic cells (< 2.5 mmHg) to mildly hypoxic cells (9 mmHg).
The oxygen enhancement ratio (OER), which is the ratio between the dose required under hypoxic conditions and the dose under oxic conditions for the same biological effect, was implemented in the model for various hypoxic levels, as shown in equation (1):
Radiotherapy has been simulated according to radiobiological principles, by using the classical Linear Quadratic formalism of cell survival [7] : (2) In equation (2), S represents the surviving cells, d the dose per fraction, n the number of fractions, D the total radiation dose and α and β are tumour specific parameters that characterize tissue radiosensitivity. According to the 040001-3 literature, the surviving fraction (SF) of head and cancer cells after a conventional dose of 2Gy is 54% [8] . Throughout this work, a hyperfractionated radiotherapy schedule has been modelled (i.e. 1.2Gy/fraction, twice daily, 5 days a week, over 7 weeks), due to its superior outcome as compared to conventional fractionation (i.e. 2Gy/fraction, once daily, 5 days a week, over 7 weeks) [9] . For hypoxic cells, the surviving fraction is determined based on equation (3) [10] :
Implementation of tumour repopulation
As mentioned above, cancer stem cells have the ability to divide symmetrically, often as a response to cell loss during therapy. As a consequence, the CSC population increases during treatment due to the unlikelihood to overcome tumour repopulation with conventional radiotherapy schedules. In the current model, the default value for the probability of symmetrical division is 1.9%. In order to evaluate the impact of this parameter on tumour development, the initially set value has been altered and increased to 5% and 10%, respectively. The interplay between hypoxia and symmetrical division probability has also been evaluated.
RESULTS
Modelling various levels of hypoxia and evaluating the impact on tumour control after radiotherapy
Since it is known that hypoxia is a strong prognostic factor in radiotherapy, the current study focused on the impact of various hypoxic levels on tumour control after hyperfractionated radiotherapy, by trying to quantify this effect as a function of treatment parameters. To fulfil this aim, tumours with various pO 2 values (mean values) ranging from 3mmHg to 9mmHg have been modelled and the effect of radiation on these tumours analysed. In these simulations, the probability of CSC symmetrical division has been kept to its pre-treatment value of 1.9%. Figure 3 shows that highly hypoxic tumours cannot be controlled with radiotherapy during a standard treatment course (7 weeks). This behaviour is also influenced by the percentage of CSC, which changes during radiotherapy, due to their higher radioresistance. Thus, according to our results, a tumour with a mean oxygen tension below 6 mmHg and a pre-treatment CSC population of 5.42% (see also Table 1 ) needs a greater dose than 84Gy (i.e. overall dose given via hyperfractionated radiotherapy) or the addition of adjuvant therapies in order to be eradicated within the required treatment time (7 weeks). Since doses larger than 84Gy via external radiotherapy are highly unlikely to be ever delivered because of normal tissue toxicity, adjuvant therapies, or other means of radiation would be the solutions to overcome this challenge. 
040001-4
Furthermore, the model showed that for each decrease in mmHg the number of radiation fractions needed for tumour eradication increases exponentially (see Fig. 4 ). It is to be noted, that in the current work, the simulated radiation therapy was not the conventional but the hyperfractionated, more efficient one. Despite its higher power, hypoxic tumours need adjuvant therapies in order to be eradicated. The large number of 1.2Gy fractions needed for tumour control in highly hypoxic tumours are clinically unreasonable. The aim of the simulation was to show different situations, including the worst-case scenario, to illustrate the powerful influence of hypoxic cells on outcome.
Modelling the interplay between hypoxia and repopulation
Another critical parameter that influences tumour control is the fraction of cancer stem cells. This fraction is dictated by cellular dynamics, governed by the division pattern of CSCs. Since they have the ability to undergo symmetrical division, this study has analysed the impact of an increased symmetrical division probability during treatment as compared to the pre-treatment value of 1.9%. Figure 5 shows the impact of different CSC symmetrical division probabilities (1.9%, 5% and 10%) on tumour response to radiation, as a function of various hypoxic levels. The graph shows the number of dose fractions required to eradicate the tumour in these scenarios. Considering that hyperfractionated radiotherapy delivers 70 doses of 1.2Gy each through a treatment course, the high number of 1.2Gy fractions represented on the ordinate of Fig. 5 , shows the high level of radioresistance imposed by the interplay between hypoxia and repopulation through CSC symmetrical division. Thus, tumours with moderate-to-severe hypoxia (pO 2 < 5mmHg) and symmetrical division probability > 5%, cannot be efficiently controlled by low LET radiation as a sole treatment, while those tumours that have a higher repopulation ability (10% symmetrical division) must have moderate-to-mild hypoxia (pO 2 > 6 mmHg) for tumour control. 
DISCUSSION AND CONCLUSIONS
The biological world is highly complex in its structure and functionality; therefore, simulations and computational models cannot reproduce precisely all aspects encountered in reality. Nevertheless, despite their limitations, models can assist in identifying gaps in research and show certain trends that could be pursued by in vitro studies. They are valuable tools in opening further research avenues and suggesting relationships between radiobiological parameters to optimize treatment outcome.
In order to achieve high tumour control after radiotherapy, there is need for personalised treatment planning that takes into account the main radiobiological parameters of each patient that could influence response to treatment. This work has presented a translational research niche, by illustrating the role of radiobiological hypoxia and cancer stem cell dynamics in tumour resistance to radiotherapy and the need for pre-treatment quantification of these parameters. Both qualitative and quantitative information on a tumour's hypoxic content represent critical information that needs to be taken into account for each patient. Similarly, identification of the cancer stem cell population through specific labelling would greatly help in treatment design and subsequent personalization. Today, there are tumour-specific CSC markers that can offer quantitative information on the CSC subpopulation within a tumour [6] . The large-scale employment of such pre-treatment assays would be critical in order to optimize treatment outcome, especially for aggressive cancers such as head and neck.
The model showed that low LET radiation as a sole agent is not sufficient for the eradication of hypoxic tumours. The challenge could be overcome by employing high LET radiation that also has an OER close to 1, which would treat hypoxic cells similar to oxic ones. Such requirements are fulfilled by alpha radiation or alpha-emitting radioisotopes that are great candidates for targeted therapies due to their ideal physical and radiobiological properties: short range, high relative biological effectiveness and an oxygen enhancement ratio nearing one.
Furthermore, several hypoxia-specific radioisotopes for pre-treatment imaging via Positron Emission Tomography have been developed and tested with varied success [9] . Currently, these are probably the least invasive and most reliable clinical instruments to investigate hypoxia in head and neck cancer patients. While numerous centers around the world have routinely implemented PET imaging before and during radiotherapy in this patient group, many would only use it for tumour identification and follow-up, without specifically targeting hypoxic regions within the tumour. Knowing that tumour radioresistance driven by the lack of oxygen is still an 
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important reason for treatment failure, hypoxia imaging followed by adjuvant therapies to overcome it, should become customary in head and neck cancer treatment.
